LETTER TO THE EDITOR

High frequency of CD29\textsuperscript{high} intermediate monocytes correlates with the activity of chronic graft-versus-host disease

To the Editor:

Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT) (1, 2). ‘Trial-and-error system’ remains the only way to identify the effectiveness of immunosuppressive drug in the individual patient, and valid biomarkers for cGVHD are eagerly needed to identify the response to the drug (3, 4). Monocyte-derived interleukin-10 (IL-10) spot-forming cells (SFCs) can be used as a biomarker for evaluating the activity of cGVHD (5). Recently, monocytes have been classified into three subpopulations (6). Among them, CD14\textsuperscript{++}CD16\textsuperscript{−} intermediate monocytes are found at low frequency, but they have unique features and expand with cytokine treatment and in inflammation (7). Now, we have demonstrated that CD29\textsuperscript{high} intermediate monocytes increased in cGVHD. These results could be clinically relevant for treatment strategies.

We have updated our published results (5) in this study by adding thirty additional samples from 57 previous and three new patients for flow cytometric analysis because a new standard of monocyte phenotypes was reported (6). Patients were subclassified into those with no, active, and inactive cGVHD as previously described (5, 8, 9). Peripheral blood mononuclear cells (PBMCs) were obtained from patients who underwent allogeneic HSCT between 2000 and 2012 with no evidence of infection. Fresh samples were obtained and assayed from patients between 6 and 139 months (mean: 47.9 months) after HSCT. The study was registered (UMIN-Clinical Trials Registry: 000006733).

First, we have performed flow cytometric analysis of the expression of CD29, a ligand of fibronectin, and intracellular (IC) IL-10 in monocytes after stimulation with or without lipopolysaccharide (LPS) in patients after HSCT (Fig. 1A). The absolute number of intermediate monocytes, but neither classical nor nonclassical monocytes, increased significantly in patients with active cGVHD compared with those with no or inactive cGVHD (P < 0.05) (Fig. 1B). The expression of CD29 on intermediate monocytes was significantly higher (P < 0.05) in patients with active cGVHD than those with no or inactive cGVHD. CD29 expression of monocytes increased after reacting with fibronectin as we have reported (5). Fibronectin strongly deposited under the basal layer of skin in cutaneous cGVHD (5, 10). Moreover, the expressions of IC IL-10 on intermediate monocytes from patients with active cGVHD stimulated both with and without LPS were significantly higher (P < 0.05) than those with no or inactive cGVHD (Fig. 1B). These results suggest that CD29\textsuperscript{high} intermediate monocytes were the main producer of IL-10 during active cGVHD.

Secondly, we studied chemokine/homing receptors on monocytes. Classical monocytes represented with lower expression of CX3CR1 (P < 0.01) and higher expression of CCR2 (P < 0.01) and CD62L (P < 0.05) than each expression of nonclassical monocytes (Fig. 1C). Intermediate monocytes showed intermediate expressions for CX3CR1, CCR2, and CD62L between classical and non-classical monocytes. Namba et al. (11) suggested that CX3CR1\textsuperscript{+} monocytes might be recruited from the circulation to the fractalkine\textsuperscript{+} epidermis in cGVHD. CCR2 is a receptor for monocyte chemoattractant protein-1 and it involved in migration of monocytes to inflammatory site. CD62L has a key role in adherence of monocytes to vascular endothelium from the blood (12). Thus, migration of blood monocytes into target organ of cGVHD might be controlled by chemokine/homing receptors.

In summary, the findings described here have demonstrated that flow cytometric analysis of intermediate monocytes can be used, as a simple and useful biomarker, for...
A CD29

No chronic GVHD
Active chronic GVHD
Inactive chronic GVHD

Classical monocyte (CD14++CD16–)
Intermediate monocyte (CD14++CD16+)
Nonclassical monocyte (CD14+CD16++)

IC IL-10
LPS (–)
LPS (+)

0
100
200
300
400
Absolute count in PB (/µL)

Classical monocyte Intermediate monocyte Nonclassical monocyte

CD29
IC IL-10
LPS (–)
LPS (+)

0
25
50
75
100
(MFI)

Classical monocyte Intermediate monocyte Nonclassical monocyte

CD62L
CCR2
CX3CR1

0
20
40
60
80
100
150
200
250
300
(MFI)

Classical monocyte Intermediate monocyte Nonclassical monocyte

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
monitoring the activity of cGVHD. When patients enter into non-active cGVHD clinically, intermediate monocytes may be used for when to quit immunosuppressants properly.

Acknowledgements
This study was supported by a Research Grant for Allergic Disease and Immunology (H20-015) from the Japanese Ministry of Health, Labor, and Welfare.

Conflict of interest
The authors declare no competing financial interests.

References
1. Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. *Haematologica* 2011;96:1678–84.
2. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. *Leukemia* 2003;17:869–75.
3. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2011;17:1–17.
4. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. *Biol Blood Marrow Transplant* 2006;12:126–37.
5. Hirayama M, Azuma E, Nakagawa-Nakazawa A, Kumamoto T, Iwamoto S, Amano K, Tamaki S, Usui E, Komada Y. Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease. *Haematologica* 2013;98:41–9.
6. Ziegler-Heitbrock L, Anuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. *Blood* 2010;116: e74–80.
7. Skrzeczynska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Prijma J. Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. *Scand J Immunol* 2008;67:152–9.
8. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, Ritz J. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. *Clin Cancer Res* 2007;13:6107–14.
9. Filipovic AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant* 2005;11:945–56.
10. van der Straaten HM, Cannings-van Dijk MR, Verdonck LF, Castigliego D, Borst HP, Aten J, Fijnheer R. Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. *J Invest Dermatol* 2004;123:1057–62.
11. Namba N, Shinagawa K, Fujii N, Maeda Y, Ishimaru F, Ikeda K, Matsui T, Tanimoto M, Katayama Y. Predominant infiltration of monocytes in chronic graft-versus-host disease. *Transplantation* 2007;83:220–4.
12. Xu H, Manivannan A, Crane I, Dawson R, Liversidge J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. *Blood* 2008;112:1166–74.

Masahiro Hirayama1, Eiichi Azuma1, Shotaro Iwamoto1, Keishiro Amano1, Atsuko Nakazawa2, Shigeisa Tamaki3, Eiji Usui3, Yoshihiro Komada1

1Department of Pediatrics and Cell Transplantation, Mie University Graduate School of Medicine, Tsu, Mie; 2Division of Pathology, Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Setagaya, Tokyo; 3Department of Internal Medicine, Ise Red Cross Hospital, Ise, Mie Japan

Correspondence Masahiro Hirayama, MD, PhD, Department of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. Tel: +81 59 232 1111; Fax: +81 59 231 5213; e-mail: hirayama@clin.med.mie-u.ac.jp

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd